Fibrinolytic therapy may be effective in the treatment of ischemic stroke, and clinical trials are under way. We evaluated two fibrinolytic agents, an analogue of tissue plasminogen activator (Fb-Fb-CF, the catalytic fragment of the tissue plasminogen activator molecule with a prolonged serum half-life, n = 10) and streptokinase (n=7), in a rabbit model of embolic stroke. Both agents were given 3 hours after stroke onset, a time relevant to the clinical setting. Fb-Fb-CF was significantly better (p<0.04) than saline (n=7) in restoring blood Bow to previously occluded intracranial arteries, but streptokinase was ineffective. Neither fibrinolytic agent was associated with a substantial risk for intracerebral hemorrhagic side effects. Our study demonstrates that Fb-Fb-CF can safely and effectively reperfuse rabbit intracranial arteries 3 hours after occlusion, while streptokinase does not. © 1990 American Heart Association, Inc.
CITATION STYLE
Phillips, D. A., Fisher, M., Davis, M. A., Smith, T. W., & Pang, R. H. L. (1990). Delayed treatment with a t-pa analogue and streptokinase in a rabbit embolic stroke model. Stroke, 21(4), 602–605. https://doi.org/10.1161/01.STR.21.4.602
Mendeley helps you to discover research relevant for your work.